Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stenoparib companion diagnostic - Allarity Therapeutics

Next Previous
Search
Drug Profile

Stenoparib companion diagnostic - Allarity Therapeutics

Alternative Names: 2X 121 companion diagnostic; 2X-121 DRP®

Latest Information Update: 24 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical Prognosis Institute
  • Developer Allarity Therapeutics; Oncology Venture US
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 22 Oct 2024 Allarity Therapeutics has patents pending for Stenoparib companion diagnostic in the Europe, US, Japan, China, Australia, and India
  • 22 Oct 2024 European Patent Office (EPO) intends to grant a patent for Allarity’s Drug Response Predictor (DRP®) diagnostic for stenoparib
  • 13 Sep 2024 Allarity Therapeutics re-initiates the phase II PREDICT 2X-121 trial in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Monotherapy, Recurrent) in USA and United Kingdom (PO) (NCT03878849) (EudraCT2020-000539-31)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top